These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38761788)

  • 1. CDK4/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: A real-world and propensity score-adjusted comparison.
    Coutinho-Almeida J; Silva AS; Redondo P; Rodrigues PP; Ferreira A
    Cancer Treat Res Commun; 2024; 40():100818. PubMed ID: 38761788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
    Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
    Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole
    Jhaveri K; O'Shaughnessy J; Fasching PA; Tolaney SM; Yardley DA; Sharma VK; Biswas C; Thuerigen A; Pathak P; Rugo HS
    Ther Adv Med Oncol; 2023; 15():17588359231216095. PubMed ID: 38107828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis.
    Tong F; Lu Y; Ma HF; Shen J
    Heliyon; 2024 Jun; 10(11):e31583. PubMed ID: 38832268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
    Eser K; Önder AH; Sezer E; Çil T; İnal A; Öztürk B; Erçolak V; Duman BB; Çelik H; Köşeci T; Kesen O
    BMC Cancer; 2022 May; 22(1):516. PubMed ID: 35525929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
    Reinert T; Barrios CH
    Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
    Ha MJ; Singareeka Raghavendra A; Kettner NM; Qiao W; Damodaran S; Layman RM; Hunt KK; Shen Y; Tripathy D; Keyomarsi K
    Int J Cancer; 2022 Jun; 150(12):2025-2037. PubMed ID: 35133007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data.
    Abdel-Razeq H; Sharaf B; AlMasri R; Abdel-Razeq R; Tamimi F; Khader O; Salama O; Abunasser M; Edaily S; Abdulelah H
    Cancer Manag Res; 2022; 14():1033-1041. PubMed ID: 35300061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.
    Fasching PA; Delea TE; Lu YS; De Boer R; Hurvitz SA; Moynahan A; Chandiwana D; Lanoue B; Hu H; Thuerigen A; O'Shaughnessy J
    Cancer Manag Res; 2021; 13():8179-8189. PubMed ID: 34754238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
    Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
    J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
    DeMichele A; Cristofanilli M; Brufsky A; Liu X; Mardekian J; McRoy L; Layman RM; Emir B; Torres MA; Rugo HS; Finn RS
    Breast Cancer Res; 2021 Mar; 23(1):37. PubMed ID: 33761995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis.
    Brufsky A; Liu X; Li B; McRoy L; Layman RM
    Front Oncol; 2022; 12():865292. PubMed ID: 35860587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
    Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast Cancer.
    Zhao JJ; Fong KY; Chan YH; Tey J; Dawood S; Lee SC; Finn RS; Sundar R; Lim JSJ
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760527
    [No Abstract]   [Full Text] [Related]  

  • 18. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
    Liu Y; Wu J; Ji Z; Chen L; Zou J; Zheng J; Lin W; Cai J; Chen Y; Zheng D; Chen Y; Li Z
    BMC Cancer; 2023 Aug; 23(1):816. PubMed ID: 37653504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line CDK4/6 inhibitor-based combinations for HR+/HER2- advanced breast cancer: A Bayesian network meta-analysis.
    Guo X; Zhou Y; Zhang K; Lu W; Zhong X; Wu S; Shen L; Chen H; Chen Y
    J Evid Based Med; 2024 Mar; 17(1):106-118. PubMed ID: 38102891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.